Arg216
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.1.1
Powered by Cell Signaling Technology
Home > Mono-methylation Site Page: > Arg216  -  PAI-RBP1 (human)

Site Information
GLkHEDKrGGsGsHN   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 6009859
Available spectra:  2 CST

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 )
Disease tissue studied:
colorectal cancer ( 15 , 18 , 19 , 20 , 21 , 22 ) , colorectal carcinoma ( 15 , 18 , 19 , 20 , 21 , 22 ) , gastric cancer ( 10 ) , lung cancer ( 6 ) , non-small cell lung cancer ( 6 , 7 , 8 , 9 , 11 , 12 ) , non-small cell lung adenocarcinoma ( 6 , 8 ) , non-small cell large cell lung carcinoma ( 6 ) , non-small cell squamous cell lung carcinoma ( 12 ) , teratoma ( 17 )
Relevant cell line - cell type - tissue:

References 

1

Larsen SC, et al. (2016) Proteome-wide analysis of arginine monomethylation reveals widespread occurrence in human cells. Sci Signal 9, rs9
27577262   Curated Info

2

Geoghegan V, et al. (2015) Comprehensive identification of arginine methylation in primary T cells reveals regulatory roles in cell signalling. Nat Commun 6, 6758
25849564   Curated Info

3

Sylvestersen KB, et al. (2014) Proteomic analysis of arginine methylation sites in human cells reveals dynamic regulation during transcriptional arrest. Mol Cell Proteomics 13, 2072-88
24563534   Curated Info

4

Guo A, et al. (2014) Immunoaffinity enrichment and mass spectrometry analysis of protein methylation. Mol Cell Proteomics 13, 372-87
24129315   Curated Info

5

Bremang M, et al. (2013) Mass spectrometry-based identification and characterisation of lysine and arginine methylation in the human proteome. Mol Biosyst 9, 2231-47
23748837   Curated Info

6

Rikova K (2013) CST Curation Set: 20100; Year: 2013; Biosample/Treatment: cell line, H2228, H3122, HCC78, H661, H1781; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R Antibodies Used to Purify Peptides prior to LCMS: Mono-Methyl Arginine [mme-R] MultiMab(TM) Rabbit mAb mix Cat#: 8015
Curated Info

7

Rikova K (2013) CST Curation Set: 18851; Year: 2013; Biosample/Treatment: cell line, H3122/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R Antibodies Used to Purify Peptides prior to LCMS: Mono-Methyl Arginine [mme-R] MultiMab(TM) Rabbit mAb mix Cat#: 8015
Curated Info

8

Rikova K (2013) CST Curation Set: 18850; Year: 2013; Biosample/Treatment: cell line, H2228/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R Antibodies Used to Purify Peptides prior to LCMS: Mono-Methyl Arginine [mme-R] MultiMab(TM) Rabbit mAb mix Cat#: 8015
Curated Info

9

Rikova K (2012) CST Curation Set: 16037; Year: 2012; Biosample/Treatment: cell line, A549/iressa, gleevec, crizotinib; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R Antibodies Used to Purify Peptides prior to LCMS: Mono-Methyl Arginine (Me-R4-100) Rabbit mAb Cat#: 8015
Curated Info

10

Rikova K (2012) CST Curation Set: 16034; Year: 2012; Biosample/Treatment: cell line, MKN45/crizotinib; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R Antibodies Used to Purify Peptides prior to LCMS: Mono-Methyl Arginine [mme-R] MultiMab(TM) Rabbit mAb mix Cat#: 8015
Curated Info

11

Rikova K (2012) CST Curation Set: 16035; Year: 2012; Biosample/Treatment: cell line, H3255/iressa; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R Antibodies Used to Purify Peptides prior to LCMS: Mono-Methyl Arginine [mme-R] MultiMab(TM) Rabbit mAb mix Cat#: 8015
Curated Info

12

Rikova K (2012) CST Curation Set: 16036; Year: 2012; Biosample/Treatment: cell line, H1703/gleevec; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R Antibodies Used to Purify Peptides prior to LCMS: Mono-Methyl Arginine [mme-R] MultiMab(TM) Rabbit mAb mix Cat#: 8015
Curated Info

13

Mulhern D (2011) CST Curation Set: 13243; Year: 2011; Biosample/Treatment: cell line, HCT116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R Antibodies Used to Purify Peptides prior to LCMS: Mono-Methyl Arginine (R*GG) (D5A12) Rabbit mAb Cat#: 8711, PTMScan(R) Mono-Methyl Arginine (D5A12) Immunoaffinity Beads Cat#: 8963
Curated Info

14

Mulhern D (2011) CST Curation Set: 13240; Year: 2011; Biosample/Treatment: cell line, HCT116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R Antibodies Used to Purify Peptides prior to LCMS: Mono-Methyl Arginine (Me-R(4)-100) Rabbit mAb Cat#: 8015, PTMScan?(R) Mono-methyl arginine (r) Immunoaffinity Beads Cat#: 8163
Curated Info

15

Possemato A (2010) CST Curation Set: 9753; Year: 2010; Biosample/Treatment: cell line, HCT 116/control; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R Antibodies Used to Purify Peptides prior to LCMS: Mono-Methyl Arginine (Me-R(4)-100) Rabbit mAb Cat#: 8015
Curated Info

16

Zhou J (2010) CST Curation Set: 9113; Year: 2010; Biosample/Treatment: cell line, NTERA-2/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R
Curated Info

17

Zhou J (2010) CST Curation Set: 9112; Year: 2010; Biosample/Treatment: cell line, NCCIT/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R
Curated Info

18

Possemato A (2010) CST Curation Set: 8862; Year: 2010; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R
Curated Info

19

Possemato A (2010) CST Curation Set: 8863; Year: 2010; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R
Curated Info

20

Possemato A (2010) CST Curation Set: 8860; Year: 2010; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R
Curated Info

21

Possemato A (2009) CST Curation Set: 6001; Year: 2009; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R
Curated Info

22

Zhou J (2008) CST Curation Set: 5630; Year: 2008; Biosample/Treatment: cell line, HCT116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R
Curated Info

23

Zhou J (2008) CST Curation Set: 5631; Year: 2008; Biosample/Treatment: cell line, HCT116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R
Curated Info

24

Possemato A (2008) CST Curation Set: 3752; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R
Curated Info